Degenerative Disc Disease Treatment Market Report 2024

This Degenerative Disc Disease Treatment market report covers industry characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The degenerative disc disease treatment market size has grown strongly in recent years. It will grow from $25.33 billion in 2023 to $27.07 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to an aging population, sedentary lifestyles, advances in medical technology, increased awareness of degenerative disc disease, rising obesity rates, a higher incidence of sports injuries, and expanded access to healthcare.

The degenerative disc disease treatment market size is expected to see strong growth in the next few years. It will grow to $35.45 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth projected for the forecast period can be attributed to increasing healthcare expenditure, a rising demand for minimally invasive procedures, improved patient education, expanding clinical research, and a growing global incidence of spine disorders. Major trends expected include the integration of AI and machine learning, advancements in regenerative medicine, innovations in minimally invasive surgery, the use of wearable technology, 3D printing for custom implants, the expansion of telemedicine and remote consultations, and a focus on personalized medicine.

The growing incidence of sports injuries is expected to drive the expansion of the degenerative disc disease treatment market. Sports injuries involve physical damage or trauma sustained by athletes or individuals engaged in physical activities, often resulting from sudden impacts, overuse, or improper techniques. The rise in sports injuries is linked to factors such as increased participation rates, more rigorous training regimens, and a heightened focus on competitive performance. Degenerative disc disease treatment is utilized to manage chronic spinal pain and restore function when disc degeneration affects athletes' performance and mobility. For example, in June 2022, the National Safety Council, a US-based nonprofit organization, reported that 3.2 million people were treated in emergency departments for injuries related to sports and recreational equipment. This represents a 20% increase in injuries in 2021, with 409,224 reported injuries compared to 377,939 in 2020. As a result, the rising number of sports injuries is fueling growth in the degenerative disc disease treatment market.

Leading companies in the degenerative disc disease treatment market are focusing on developing innovative therapies, such as injectable disc cell therapy (IDCT), to enhance patient outcomes by increasing disc volume, relieving low back pain, and reducing reliance on pain medications. Injectable disc cell therapy (IDCT) is a regenerative treatment designed for symptomatic lumbar degenerative disc disease. For instance, in February 2023, DiscGenics Inc., a US-based biopharmaceutical company, received FDA regenerative medicine advanced therapy designation for its injectable disc cell therapy (IDCT), which targets symptomatic lumbar degenerative disc disease. This cutting-edge therapy employs a live progenitor cell population derived from donated adult human intervertebral disc tissue. IDCT aims to boost disc volume, alleviate low back pain, and lessen the need for pain medication in affected patients.

In January 2023, Companion Spine LLC, a US-based spine care company, acquired Backbone SAS for an undisclosed amount. This acquisition is intended to enhance Companion's portfolio of medical implants for treating spine and back pain. Backbone SAS, based in France, specializes in developing and manufacturing medical devices for spine and back pain treatment.

Major companies operating in the degenerative disc disease treatment market are Pfizer Inc., Johnson And Johnson, Sanofi S.A., AstraZeneca Plc, Novartis AG, GlaxoSmithKline PLC, Medtronic plc, Amgen Inc., Baxter International Inc., B. Braun SE, Zimmer Biomet Holdings Inc., Arthrex Inc., Ferring B.V., Biocon Limited, Integra LifeSciences Holdings Corporation, NuVasive Inc., Globus Medical Inc., Orthofix Medical Inc., RTI Surgical Holdings Inc., LifeNet Health.

North America was the largest region in the degenerative disc disease treatment market in 2023. The regions covered in the degenerative disc disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the degenerative disc disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Degenerative disc disease treatment encompasses various medical approaches designed to alleviate symptoms and enhance functionality in individuals with degenerative disc disease, a condition where the spinal discs lose their cushioning ability over time. Treatments may include physical therapy, pain management with medications, lifestyle changes, and, in some cases, surgical procedures like discectomy or spinal fusion to relieve nerve pressure and stabilize the spine.

The primary types of treatment for degenerative disc disease are conventional drugs and novel therapies. Conventional drugs involve standard medications used to manage symptoms, such as pain relievers and anti-inflammatory drugs. These medications can be administered orally or via injection and are utilized in various settings, including hospitals, ambulatory surgical centers, and orthopedic centers.

The degenerative disc disease treatment market research report is one of a series of new reports that provides degenerative disc disease treatment market statistics, including degenerative disc disease treatment industry global market size, regional shares, competitors with a degenerative disc disease treatment market share, detailed degenerative disc disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the degenerative disc disease treatment industry. This degenerative disc disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The degenerative disc disease treatment market consists of revenues earned by entities by providing services such as medical consultations, surgical procedures, and post-treatment rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The degenerative disc disease treatment market also includes sales of spinal implants, orthopedic braces, pain relief medications, physical therapy equipment, and diagnostic imaging tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.